|
1
|
Rimawi MF, Mayer IA, Forero A, Nanda R,
Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG,
Gutierrez C, et al: Multicenter phase II study of neoadjuvant
lapatinib and trastuzumab with hormonal therapy and without
chemotherapy in patients with human epidermal growth factor
receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol.
31:1726–1731. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Koeppen HK, Wright BD, Burt AD, Quirke P,
McNicol AM, Dybdal NO, Sliwkowski MX and Hillan KJ: Overexpression
of HER2/neu in solid tumours: An immunohistochemical survey.
Histopathology. 38:96–104. 2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cobleigh MA, Vogel CL, Tripathy D, Robert
NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman
G and Slamon DJ: Multinational study of the efficacy and safety of
humanized anti-HER2 monoclonal antibody in women who have
HER2-overexpressing metastatic breast cancer that has progressed
after chemotherapy for metastatic disease. J Clin Oncol.
17:2639–2648. 1999.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Neto AS, Tobias-Machado M, Wroclawski ML,
Fonseca FL, Teixeira GK, Amarante RD, Wroclawski ER and Del Giglio
A: Her-2/neu expression in prostate adenocarcinoma: A systematic
review and meta-analysis. J Urol. 184:842–850. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Minner S, Jessen B, Stiedenroth L, Burandt
E, Köllermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch
M, Brümmendorf TH, et al: Low level HER2 overexpression is
associated with rapid tumor cell proliferation and poor prognosis
in prostate cancer. Clin Cancer Res. 16:1553–1560. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Carrión-Salip D, Panosa C, Menendez JA,
Puig T, Oliveras G, Pandiella A, De Llorens R and Massaguer A:
Androgen-independent prostate cancer cells circumvent EGFR
inhibition by overexpression of alternative HER receptors and
ligands. Int J Oncol. 41:1128–1138. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Craft N, Shostak Y, Carey M and Sawyers
CL: A mechanism for hormone-independent prostate cancer through
modulation of androgen receptor signaling by the HER-2/neu tyrosine
kinase. Nat Med. 5:280–285. 1999.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Miyamoto H, Hernandez DJ and Epstein JI: A
pathological reassessment of organ-confined, Gleason score 6
prostatic adenocarcinomas that progress after radical
prostatectomy. Hum Pathol. 40:1693–1698. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kobayashi M, Ishida H, Shindo T, Niwa S,
Kino M, Kawamura K, Kamiya N, Imamoto T, Suzuki H, Hirokawa Y, et
al: Molecular analysis of multifocal prostate cancer by comparative
genomic hybridization. Prostate. 68:1715–1724. 2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lepor H and Donin NM: Gleason 6 prostate
cancer: Serious malignancy or toothless lion? Oncology (Williston
Park). 28:16–22. 2014.PubMed/NCBI
|
|
12
|
Korkes F, de Castro MG, de Cassio Zequi S,
Nardi L, Del Giglio A and de Lima Pompeo AC: Hyaluronan-mediated
motility receptor (RHAMM) immunohistochemical expression and
androgen deprivation in normal peritumoral, hyperplasic and
neoplastic prostate tissue. BJU Int. 113:822–829. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Espinoza F and Thompson J: HercepTest™
interpretation manual. Dako, 2010.
|
|
14
|
Egevad L, Delahunt B, Srigley JR and
Samaratunga H: International society of urological pathology (ISUP)
grading of prostate cancer-an ISUP consensus on contemporary
grading. APMIS. 124:433–435. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Brierley JD, Gospodarowicz MK and
Wittekind C (eds): TNM classification of malignant tumors. UICC
International Union Against Cancer, 2017.
|
|
16
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137.
2001.PubMed/NCBI View
Article : Google Scholar
|
|
18
|
Di Lorenzo G, Tortora G, D'Armiento FP, De
Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De
Placido S, Catalano G, et al: Expression of epidermal growth factor
receptor correlates with disease relapse and progression to
androgen-independence in human prostate cancer. Clin Cancer Res.
8:3438–3444. 2002.PubMed/NCBI
|
|
19
|
Rao K, Gaughan L, Robson C and McCracken
S: The role of the HER2 and HER3 in prostate cancer and their
potential as therapeutic targets. Eur J Cancer. 61 (Suppl
1)(S177)2016.
|
|
20
|
Baek KH, Hong ME, Jung YY, Lee CH, Lee TJ,
Park ES, Kim MK, Yoo JH and Lee SW: Correlation of AR, EGFR, and
HER2 expression levels in prostate cancer: Immunohistochemical
analysis and chromogenic in situ hybridization. Cancer Res Treat.
44:50–56. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yan M, Schwaederle M, Arguello D, Millis
SZ, Gatalica Z and Kurzrock R: HER2 expression status in diverse
cancers: Review of results from 37,992 patients. Cancer Metastasis
Rev. 34:157–164. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lara PN Jr, Meyers FJ, Gray CR, Edwards
RG, Gumerlock PH, Kauderer C, Tichauer G, Twardowski P, Doroshow JH
and Gandara DR: HER-2/neu is overexpressed infrequently in patients
with prostate carcinoma. Results from the California cancer
consortium screening trial. Cancer. 94:2584–2589. 2002.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sanchez KM, Sweeney CJ, Mass R, Koch MO,
Eckert GJ, Geary WA, Baldridge LA, Zhang S, Eble JN and Cheng L:
Evaluation of HER-2/neu expression in prostatic adenocarcinoma: A
requested for a standardized, organ specific methodology. Cancer.
95:1650–1655. 2002.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Muniyan S, Chen SJ, Lin FF, Wang Z, Mehta
PP, Batra SK and Lin M-F: ErbB-2 signaling plays a critical role in
regulating androgen-sensitive and castration-resistant androgen
receptor-positive prostate cancer. cells. 27:2261–2271.
2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Di Lorenzo G, Autorino R, De Laurentiis M,
Cindolo L, D'Armiento M, Bianco AR and De Placido S: HER-2/neu
receptor in prostate cancer development and progression to androgen
independence. Tumori. 90:163–170. 2004.PubMed/NCBI
|
|
26
|
Chen L, Mooso BA, Jathal MK, Madhav A,
Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L,
Vinall RL, et al: Dual EGFR/HER2 inhibition sensitizes prostate
cancer cells to androgen withdrawal by suppressing ErbB3. Clin
Cancer Res. 17:6218–6228. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Meng TC, Lee MS and Lin MF: Interaction
between protein tyrosine phosphatase and protein tyrosine kinase is
involved in androgen-promoted growth of human prostate cancer
cells. Oncogene. 19:2664–2677. 2000.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bolla M, Van Tienhoven G, Warde P, Dubois
JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C,
Billiet I, et al: External irradiation with or without long-term
androgen suppression for prostate cancer with high metastatic risk:
10-year results of an EORTC randomised study. Lancet Oncol.
11:1066–1073. 2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Denham JW, Steigler A, Lamb DS, Joseph D,
Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, et
al: Short-term neoadjuvant androgen deprivation and radiotherapy
for locally advanced prostate cancer: 10-year data from the TROG
96.01 randomised trial. Lancet Oncol. 12:451–459. 2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pendleton J, Pisters LL, Nakamura K, Anai
S and Rosser CJ: Neoadjuvant therapy before radical prostatectomy:
Where have we been? Where are we going? Urol Oncol. 25:11–18.
2007.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wilson KJ, Gilmore JL, Foley J, Lemmon MA
and Riese DJ II: Functional selectivity of EGF family peptide
growth factors: Implications for cancer. Pharmacol Ther. 122:1–8.
2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Furrer D, Paquet C, Jacob S and Diorio C:
The human epidermal growth factor receptor 2 (HER2) as a prognostic
and predictive biomarker: Molecular insights into HER2 activation
and diagnostic implications. Cancer Prognosis: pp11-13, 2018.
|
|
33
|
Ding L, Tian C, Feng S, Fida G, Zhang C,
Ma Y, Ai G, Achilefu S and Gu Y: Small sized EGFR1 and HER2
specific bifunctional antibody for targeted cancer therapy.
Theranostics. 5:378–398. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tambo M, Higashihara E, Terado Y, Nutahara
K and Okegawa T: Comparison of serum HER2/neu with
immunohistochemical HER2/neu expression for the prediction of
biochemical progression in metastatic prostate cancer. Int J Urol.
16:369–374. 2009.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Domingo-Domenech J, Fernandez PL, Filella
X, Martinez-Fernandez A, Molina R, Fernandez E, Alcaraz A, Codony
J, Gascon P and Mellado B: Serum HER2 extracellular domain predicts
an aggressive clinical outcome and biological PSA response in
hormone-independent prostate cancer patients treated with
docetaxel. Ann Oncol. 19:269–275. 2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Jathal MK, Steele TM, Siddiqui S, Mooso
BA, D'Abronzo LS, Drake CM, Whang YE and Ghosh PM: Dacomitinib, but
not lapatinib, suppressed progression in castration-resistant
prostate cancer models by preventing HER2 increase. Br J Cancer.
121:237–248. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Tome-Garcia J, Li D, Ghazaryan S, Shu L
and Wu L: ERBB2 increases metastatic potentials specifically in
androgen-insensitive prostate cancer cells. PLoS One.
9(e99525)2014.PubMed/NCBI View Article : Google Scholar
|
